1303 
‘‘(c) USE OF FUNDS.—The activities for which a grant 
under this section may be used include— 
‘‘(1) planning and constructing— 
‘‘(A) a new allopathic or osteopathic school 
of medicine in an area in which no other school 
is based; or 
‘‘(B) a branch campus of an allopathic or 
osteopathic school of medicine in an area in 
which no such school is based; 
‘‘(2) accreditation and planning activities for an 
allopathic or osteopathic school of medicine or branch 
campus; 
‘‘(3) hiring faculty and other staff to serve at an 
allopathic or osteopathic school of medicine or branch 
campus; 
‘‘(4) recruitment and enrollment of students at 
an allopathic or osteopathic school of medicine or 
branch campus; 
‘‘(5) supporting educational programs at an 
allopathic or osteopathic school of medicine or branch 
campus; 
‘‘(6) modernizing infrastructure or curriculum 
at an existing allopathic or osteopathic school of med-
icine or branch campus thereof;
1304 
‘‘(7) expanding infrastructure or curriculum at 
existing an allopathic or osteopathic school of medi-
cine or branch campus; and 
‘‘(8) other activities that the Secretary deter-
mines further the development, improvement, and ex-
pansion of an allopathic or osteopathic school of med-
icine or branch campus thereof. 
‘‘(d) DEFINITIONS.—In this section: 
‘‘(1) The term ‘branch campus’ means a geo-
graphically separate site at least 100 miles from the 
main campus of a school of medicine where at least 
one student completes at least 60 percent of the stu-
dent’s training leading to a degree of doctor of medi-
cine. 
‘‘(2) The term ‘institution of higher education’ 
has the meaning given to such term in section 101(a) 
of the Higher Education Act of 1965. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$1,000,000,000, to remain available until expended.’’. 
SEC. 616. GAO STUDY ON PUBLIC HEALTH WORKFORCE. 
(a) IN GENERAL.—The Comptroller General of the 
United States shall conduct a study on the public health 
workforce in the United States during the COVID–19 pan-
demic.
1305 
(b) TOPICS.—The study under subsection (a) shall ad-
dress— 
(1) existing gaps in the Federal, State, local, 
Tribal, and territorial public health workforce, in-
cluding— 
(A) epidemiological and disease interven-
tion specialists needed during the pandemic for 
contact tracing, laboratory technicians necessary 
for testing, community health workers for com-
munity supports and services, and other staff 
necessary for contact tracing, testing, or surveil-
lance activities; and 
(B) other personnel needed during the 
COVID–19 pandemic; 
(2) challenges associated with the hiring, recruit-
ment, and retention of the Federal, State, local, Trib-
al, and territorial public health workforce; and 
(3) recommended steps the Federal Government 
should take to improve hiring, recruitment, and reten-
tion of the public health workforce. 
(c) REPORT.—Not later than December 1, 2022, the 
Comptroller General shall submit to the Congress a report 
on the findings of the study conducted under this section.
1306 
SEC. 617. LONGITUDINAL STUDY ON THE IMPACT OF 
COVID–19 ON RECOVERED PATIENTS. 
Part A of title IV of the Public Health Service Act 
(42 U.S.C. 281 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 404O. LONGITUDINAL STUDY ON THE IMPACT OF 
COVID–19 ON RECOVERED PATIENTS. 
‘‘(a) IN GENERAL.—The Director of NIH, in consulta-
tion with the Director of the Centers for Disease Control 
and Prevention, shall conduct a longitudinal study, over 
not less than 10 years, on the full impact of SARS–CoV– 
2 or COVID–19 on infected individuals, including both 
short-term and long-term health impacts. 
‘‘(b) TIMING.—The Director of NIH shall begin enroll-
ing patients in the study under this section not later than 
6 months after the date of enactment of this section. 
‘‘(c) REQUIREMENTS.—The study under this section 
shall— 
‘‘(1) be nationwide; 
‘‘(2) include diversity of enrollees to account for 
gender, age, race, ethnicity, geography, comorbidities, 
and underrepresented populations, including preg-
nant and lactating women; 
‘‘(3) study individuals with COVID–19 who ex-
perienced mild symptoms, such individuals who expe-
1307 
rienced moderate symptoms, and such individuals 
who experienced severe symptoms; 
‘‘(4) monitor the health outcomes and symptoms 
of individuals with COVID–19, or who had prenatal 
exposure to SARS–CoV–2 or COVID–19, including 
lung capacity and function, and immune response, 
taking into account any pharmaceutical interventions 
such individuals may have received; 
‘‘(5) monitor the mental health outcomes of indi-
viduals with COVID–19, taking into account any 
interventions that affected mental health; and 
‘‘(6) monitor individuals enrolled in the study 
not less frequently than twice per year after the first 
year of the individual’s infection with SARS–CoV–2. 
‘‘(d) PUBLIC-PRIVATE
RESEARCH
NETWORK.—For 
purposes of carrying out the study under this section, the 
Director of NIH may develop a network of public-private 
research partners, provided that all research, including the 
research carried out through any such partner, is available 
publicly. 
‘‘(e) SUMMARIES OF FINDINGS.—The Director of NIH 
shall make public a summary of findings under this section 
not less frequently than once every 3 months for the first 
2 years of the study, and not less frequently than every 6 
months thereafter. Such summaries may include informa-
1308 
tion about how the findings of the study under this section 
compare with findings from research conducted abroad. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$200,000,000, to remain available until expended.’’. 
SEC. 618. RESEARCH ON THE MENTAL HEALTH IMPACT OF 
COVID–19. 
(a) IN GENERAL.—The Secretary, acting through the 
Director of the National Institute of Mental Health, shall 
conduct or support research on the mental health con-
sequences of SARS–CoV–2 or COVID–19. 
(b) USE OF FUNDS.—Research under subsection (a) 
may include the following: 
(1) Research on the mental health impact of 
SARS–CoV–2 or COVID–19 on health care providers, 
including— 
(A) traumatic stress; 
(B) psychological distress; and 
(C) psychiatric disorders. 
(2) Research on the impact of SARS–CoV–2 or 
COVID–19 stressors on mental health over time. 
(3) Research to strengthen the mental health re-
sponse to SARS–CoV–2 or COVID–19, including 
adapting to and maintaining or providing additional 
services for new or increasing mental health needs.
1309 
(4) Research on the reach, efficiency, effective-
ness, and quality of digital mental health interven-
tions. 
(5) Research on effectiveness of strategies for im-
plementation and delivery of evidence-based mental 
health interventions and services for underserved pop-
ulations. 
(6) Research on suicide prevention. 
(c) RESEARCH COORDINATION.—The Secretary shall 
coordinate activities under this section with similar activi-
ties conducted by national research institutes and centers 
of the National Institutes of Health to the extent that such 
institutes and centers have responsibilities that are related 
to the mental health consequences of SARS–CoV–2 or 
COVID–19. 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$200,000,000, to remain available until expended. 
SEC. 619. EMERGENCY MENTAL HEALTH AND SUBSTANCE 
USE TRAINING AND TECHNICAL ASSISTANCE 
CENTER. 
Subpart 3 of part B of title V of the Public Health 
Service Act (42 U.S.C. 290bb–31 et seq.) is amended by in-
serting after section 520A (42 U.S.C. 290bb–32) the fol-
lowing:
1310 
‘‘SEC. 520B. EMERGENCY MENTAL HEALTH AND SUBSTANCE 
USE TRAINING AND TECHNICAL ASSISTANCE 
CENTER. 
‘‘(a) ESTABLISHMENT.—The Secretary, acting through 
the Assistant Secretary, shall establish or operate a center 
to be known as the Emergency Mental Health and Sub-
stance Use Training and Technical Assistance Center (re-
ferred to in this section as the ‘Center’) to provide technical 
assistance and support— 
‘‘(1) to public or nonprofit entities seeking to es-
tablish or expand access to mental health and sub-
stance use prevention, treatment, and recovery sup-
port services, and increase awareness of such services; 
and 
‘‘(2) to public health professionals, health care 
professionals and support staff, essential workers (as 
defined by a State, Tribe, locality, or territory), and 
members of the public to address the trauma, stress, 
and mental health needs associated with an emer-
gency period. 
‘‘(b) ASSISTANCE AND SUPPORT.—The assistance and 
support provided under subsection (a) shall include assist-
ance and support with respect to— 
‘‘(1) training on identifying signs of trauma, 
stress, and mental health needs;
1311 
‘‘(2) providing accessible resources to assist indi-
viduals and families experiencing trauma, stress, or 
other mental health needs during and after an emer-
gency period; 
‘‘(3) providing resources for substance use dis-
order prevention, treatment, and recovery designed to 
assist individuals and families during and after an 
emergency period; 
‘‘(4) the provision of language access services, in-
cluding translation services, interpretation, or other 
such services for individuals with limited English 
speaking proficiency or people with disabilities; and 
‘‘(5) evaluation and improvement, as necessary, 
of the effectiveness of such services provided by public 
or nonprofit entities. 
‘‘(c) BEST PRACTICES.—The Center shall periodically 
issue best practices for use by organizations seeking to pro-
vide mental health services or substance use disorder pre-
vention, treatment, or recovery services to individuals dur-
ing and after an emergency period. 
‘‘(d) EMERGENCY PERIOD.—In this section, the term 
‘emergency period’ has the meaning given such term in sec-
tion 1135(g)(1)(A) of the Social Security Act.
1312 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$20,000,000 for each of fiscal years 2021 and 2022.’’. 
SEC. 620. IMPORTANCE OF THE BLOOD AND PLASMA SUP-
PLY. 
(a) IN GENERAL.—Section 3226 of the CARES Act 
(Public Law 116–136) is amended— 
(1) in the section heading after ‘‘BLOOD’’ by in-
serting ‘‘AND PLASMA’’; and 
(2) by inserting after ‘‘blood’’ each time it ap-
pears ‘‘and plasma’’. 
(b) CONFORMING AMENDMENT.—The item relating to 
section 3226 in the table of contents in section 2 of the 
CARES Act (Public Law 116–136) is amended to read as 
follows: 
‘‘Sec. 3226. Importance of the blood and plasma supply.’’. 
Subtitle B—Assistance for 
Individuals and Families 
SEC. 631. REIMBURSEMENT FOR ADDITIONAL HEALTH 
SERVICES RELATING TO CORONAVIRUS. 
Title V of division A of the Families First Coronavirus 
Response Act (Public Law 116–127; 134 Stat. 182) is 
amended under the heading ‘‘Department of Health and 
Human Services—Office of the Secretary—Public Health 
and Social Services Emergency Fund’’ by inserting ‘‘, or 
treatment related to SARS–CoV–2 or COVID–19 for unin-
1313 
sured individuals’’ after ‘‘or visits described in paragraph 
(2) of such section for uninsured individuals’’. 
SEC. 632. CENTERS FOR DISEASE CONTROL AND PREVEN-
TION COVID–19 RESPONSE LINE. 
(a) IN GENERAL.—During the public health emergency 
declared by the Secretary pursuant to section 319 of the 
Public Health Service Act (42 U.S.C. 247d) on January 
31, 2020, with respect to COVID–19, the Secretary, acting 
through the Director of the Centers for Disease Control and 
Prevention, shall maintain a toll-free telephone number to 
address public health queries, including questions con-
cerning COVID–19. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$10,000,000, to remain available until expended. 
SEC. 633. GRANTS TO ADDRESS SUBSTANCE USE DURING 
COVID–19. 
(a) IN GENERAL.—The Assistant Secretary for Mental 
Health and Substance Use of the Department of Health and 
Human Services (in this section referred to as the ‘‘Assist-
ant Secretary’’), in consultation with the Director of the 
Centers for Disease Control and Prevention, shall award 
grants to States, political subdivisions of States, Tribes, 
Tribal organizations, and community-based entities to ad-
dress the harms of drug misuse, including by—
1314 
(1) preventing and controlling the spread of in-
fectious diseases, such as HIV/AIDS and viral hepa-
titis, and the consequences of such diseases for indi-
viduals with substance use disorder; 
(2) connecting individuals at risk for or with a 
substance use disorder to overdose education, coun-
seling, and health education; or 
(3) encouraging such individuals to take steps to 
reduce the negative personal and public health im-
pacts of substance use or misuse during the emergency 
period. 
(b) CONSIDERATIONS.—In awarding grants under this 
section, the Assistant Secretary shall prioritize grants to 
applicants proposing to serve areas with— 
(1) a high proportion of people who meet criteria 
for dependence on or abuse of illicit drugs who have 
not received any treatment; 
(2) high drug overdose death rates; 
(3) high telemedicine infrastructure needs; and 
(4) high behavioral health and substance use dis-
order workforce needs. 
(c) DEFINITION.—In this section, the term ‘‘emergency 
period’’ has the meaning given to such term in section 
1135(g)(1)(B) of the Social Security Act (42 U.S.C. 1320b– 
5(g)(1)(B))).
1315 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$10,000,000, to remain available until expended. 
SEC. 634. GRANTS TO SUPPORT INCREASED BEHAVIORAL 
HEALTH NEEDS DUE TO COVID–19. 
(a) IN GENERAL.—The Secretary, acting through the 
Assistant Secretary of Mental Health and Substance Use, 
shall award grants to States, political subdivisions of 
States, Indian Tribes and Tribal organizations, commu-
nity-based entities, and primary care and behavioral health 
organizations to address behavioral health needs caused by 
the public health emergency declared pursuant to section 
319 of the Public Health Service Act (42 U.S.C. 247d) with 
respect to COVID–19. 
(b) USE OF FUNDS.—An entity that receives a grant 
under subsection (a) may use funds received through such 
grant to— 
(1) increase behavioral health treatment and pre-
vention capacity, including to— 
(A) promote coordination among local enti-
ties; 
(B) train the behavioral health workforce, 
relevant stakeholders, and community members;
1316 
(C) upgrade technology to support effective 
delivery of health care services through telehealth 
modalities; 
(D) purchase medical supplies and equip-
ment for behavioral health treatment entities and 
providers; 
(E) address surge capacity for behavioral 
health needs such as through mobile units; and 
(F) promote collaboration between primary 
care and mental health providers; and 
(2) support or enhance behavioral health services, 
including— 
(A) emergency crisis intervention, including 
mobile crisis units, 24/7 crisis call centers, and 
medically staffed crisis stabilization programs; 
(B) screening, assessment, diagnosis, and 
treatment; 
(C) mental health awareness trainings; 
(D) evidence-based suicide prevention; 
(E) evidence-based integrated care models; 
(F) community recovery supports; 
(G) outreach to underserved and minority 
communities; and 
(H) for front line health care workers.
1317 
(c) PRIORITY.—The Secretary shall give priority to 
applicants proposing to serve areas with a high number of 
COVID–19 cases. 
(d) EVALUATION.—An entity that receives a grant 
under this section shall prepare and submit an evaluation 
to the Secretary at such time, in such manner, and con-
taining such information as the Secretary may reasonably 
require, including— 
(1) an evaluation of activities carried out with 
funds received through the grant; and 
(2) a process and outcome evaluation. 
(e) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$50,000,000 for each of fiscal years 2021 and 2022, to re-
main available until expended. 
Subtitle C—Assistance to Tribes 
SEC. 641. IMPROVING STATE, LOCAL, AND TRIBAL PUBLIC 
HEALTH SECURITY. 
Section 319C–1 of the Public Health Service Act (42 
U.S.C. 247d–3a) is amended— 
(1) in the section heading, by striking ‘‘AND 
LOCAL’’ and inserting ‘‘, LOCAL, AND TRIBAL’’; 
(2) in subsection (b)— 
(A) in paragraph (1)—
1318 
(i) in subparagraph (B), by striking 
‘‘or’’ at the end; 
(ii) in subparagraph (C), by striking 
‘‘and’’ at the end and inserting ‘‘or’’; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(D) be an Indian Tribe, Tribal organization, or 
a consortium of Indian Tribes or Tribal organiza-
tions; and’’; and 
(B) in paragraph (2)— 
(i) in the matter preceding subpara-
graph (A), by inserting ‘‘, as applicable’’ 
after ‘‘including’’; 
(ii) in subparagraph (A)(viii)— 
(I) by inserting ‘‘and Tribal’’ 
after ‘‘with State’’; 
(II) by striking ‘‘(as defined in 
section 8101 of the Elementary and 
Secondary Education Act of 1965)’’ 
and inserting ‘‘and Tribal educational 
agencies (as defined in sections 8101 
and 6132, respectively, of the Elemen-
tary and Secondary Education Act of 
1965)’’; and
1319 
(III) by inserting ‘‘and Tribal’’ 
after ‘‘and State’’; 
(iii) in subparagraph (G), by striking 
‘‘and tribal’’ and inserting ‘‘Tribal, and 
urban Indian organization’’; and 
(iv) in subparagraph (H), by inserting 
‘‘, Indian Tribes, and urban Indian organi-
zations’’ after ‘‘public health’’; 
(3) in subsection (e), by inserting ‘‘Indian 
Tribes, Tribal organizations, urban Indian organiza-
tions,’’ after ‘‘local emergency plans,’’; 
(4) in subsection (g)(1), by striking ‘‘tribal offi-
cials’’ and inserting ‘‘Tribal officials’’; 
(5) in subsection (h)— 
(A) in paragraph (1)(A)— 
(i) by striking ‘‘through 2023’’ and in-
serting ‘‘and 2020’’; and 
(ii) by inserting before the period ‘‘; 
and $690,000,000 for each of fiscal years 
2021 through 2024 for awards pursuant to 
paragraph (3) (subject to the authority of 
the Secretary to make awards pursuant to 
paragraphs (4) and (5)) and paragraph (8), 
of which not less than $5,000,000 shall be
1320 
reserved each fiscal year for awards under 
paragraph (8)’’; 
(B) in paragraph (2)(B), by striking ‘‘trib-
al public’’ and inserting ‘‘Tribal public’’; 
(C) in the heading of paragraph (3), by in-
serting ‘‘FOR STATES’’ after ‘‘AMOUNT’’; and 
(D) by adding at the end the following: 
‘‘(8) TRIBAL ELIGIBLE ENTITIES.— 
‘‘(A) 
DETERMINATION
OF
FUNDING 
AMOUNT.— 
‘‘(i) IN GENERAL.—The Secretary shall 
award at least 10 cooperative agreements 
under this section, in amounts not less than 
the minimum amount determined under 
clause (ii), to eligible entities described in 
subsection (b)(1)(D) that submits to the Sec-
retary an application that meets the cri-
teria of the Secretary for the receipt of such 
an award and that meets other reasonable 
implementation conditions established by 
the Secretary, in consultation with Indian 
Tribes, for such awards. If the Secretary re-
ceives more than 10 applications under this 
section from eligible entities described in 
subsection (b)(1)(D) that meet the criteria
1321 
and conditions described in the previous 
sentence, the Secretary, in consultation with 
Indian 
Tribes, 
may 
make 
additional 
awards under this section to such entities. 
‘‘(ii) MINIMUM
AMOUNT.—In deter-
mining the minimum amount of an award 
pursuant to clause (i), the Secretary, in 
consultation with Indian Tribes, shall first 
determine an amount the Secretary con-
siders appropriate for the eligible entity. 
‘‘(B) 
AVAILABLE
UNTIL
EXPENDED.— 
Amounts provided to a Tribal eligible entity 
under a cooperative agreement under this section 
for a fiscal year and remaining unobligated at 
the end of such year shall remain available to 
such entity during the entirety of the perform-
ance period, for the purposes for which said 
funds were provided. 
‘‘(C) NO
MATCHING
REQUIREMENT.—Sub-
paragraphs (B), (C), and (D) of paragraph (1) 
shall not apply with respect to cooperative agree-
ments awarded under this section to eligible enti-
ties described in subsection (b)(1)(D).’’; and 
(6) by adding at the end the following:
1322 
‘‘(l) SPECIAL RULES RELATED TO TRIBAL ELIGIBLE 
ENTITIES.— 
‘‘(1) MODIFICATIONS.—After consultation with 
Indian Tribes, the Secretary may make necessary and 
appropriate modifications to the program under this 
section to facilitate the use of the cooperative agree-
ment program by eligible entities described in sub-
section (b)(1)(D). 
‘‘(2) WAIVERS.— 
‘‘(A) IN GENERAL.—Except as provided in 
subparagraph (B), the Secretary may waive or 
specify alternative requirements for any provi-
sion of this section (including regulations) that 
the Secretary administers in connection with 
this section if the Secretary finds that the waiver 
or alternative requirement is necessary for the ef-
fective delivery and administration of this pro-
gram with respect to eligible entities described in 
subsection (b)(1)(D). 
‘‘(B) EXCEPTION.—The Secretary may not 
waive or specify alternative requirements under 
subparagraph (A) relating to labor standards or 
the environment. 
‘‘(3) CONSULTATION.—The Secretary shall con-
sult with Indian Tribes and Tribal organizations on
1323 
the design of this program with respect to such Tribes 
and organizations to ensure the effectiveness of the 
program in enhancing the security of Indian Tribes 
with respect to public health emergencies. 
‘‘(4) REPORTING.— 
‘‘(A) IN GENERAL.—Not later than 2 years 
after the date of enactment of this subsection, 
and as an addendum to the biennial evaluations 
required under subsection (k), the Secretary, in 
coordination with the Director of the Indian 
Health Service, shall— 
‘‘(i) conduct a review of the implemen-
tation of this section with respect to eligible 
entities described in subsection (b)(1)(D), 
including any factors that may have lim-
ited its success; and 
‘‘(ii) submit a report describing the re-
sults of the review described in clause (i) 
to— 
‘‘(I) the Committee on Indian Af-
fairs, the Committee on Health, Edu-
cation, Labor and Pensions, and the 
Committee on Appropriations of the 
Senate; and
1324 
‘‘(II) the Subcommittee for Indig-
enous Peoples of the United States of 
the Committee on Natural Resources, 
the Committee on Energy and Com-
merce, and the Committee on Appro-
priations of the House of Representa-
tives. 
‘‘(B) ANALYSIS OF TRIBAL PUBLIC HEALTH 
EMERGENCY INFRASTRUCTURE LIMITATION.—The 
Secretary shall include in the initial report sub-
mitted under subparagraph (A) a description of 
any public health emergency infrastructure limi-
tation encountered by eligible entities described 
in subsection (b)(1)(D).’’. 
SEC. 642. PROVISION OF ITEMS TO INDIAN PROGRAMS AND 
FACILITIES. 
(a) 
STRATEGIC
NATIONAL
STOCKPILE.—Section 
319F–2(a)(3)(G) of the Public Health Service Act (42 
U.S.C. 247d–6b(a)(3)(G)) is amended by inserting ‘‘, and, 
in the case that the Secretary deploys the stockpile under 
this subparagraph, ensure, in coordination with the appli-
cable States and programs and facilities, that appropriate 
drugs, vaccines and other biological products, medical de-
vices, and other supplies are deployed by the Secretary di-
rectly to health programs or facilities operated by the In-
1325 
dian Health Service, an Indian Tribe, a Tribal organiza-
tion (as those terms are defined in section 4 of the Indian 
Self-Determination and Education Assistance Act (25 
U.S.C. 5304)), or an inter-Tribal consortium (as defined 
in section 501 of the Indian Self-Determination and Edu-
cation Assistance Act (25 U.S.C. 5381)) or through an 
urban Indian organization (as defined in section 4 of the 
Indian Health Care Improvement Act), while avoiding du-
plicative distributions to such programs or facilities’’ before 
the semicolon. 
(b) DISTRIBUTION OF QUALIFIED PANDEMIC OR EPI-
DEMIC PRODUCTS TO IHS FACILITIES.—Title III of the 
Public Health Service Act (42 U.S.C. 241 et seq.) is amend-
ed by inserting after section 319F–4 the following: 
‘‘SEC. 319F–5. DISTRIBUTION OF QUALIFIED PANDEMIC OR 
EPIDEMIC PRODUCTS TO INDIAN PROGRAMS 
AND FACILITIES. 
‘‘In the case that the Secretary distributes qualified 
pandemic or epidemic products (as defined in section 
319F–3(i)(7)) to States or other entities, the Secretary shall 
ensure, in coordination with the applicable States and pro-
grams and facilities, that, as appropriate, such products are 
distributed directly to health programs or facilities operated 
by the Indian Health Service, an Indian Tribe, a Tribal 
organization (as those terms are defined in section 4 of the
1326 
Indian Self-Determination and Education Assistance Act 
(25 U.S.C. 5304)), or an inter-Tribal consortium (as de-
fined in section 501 of the Indian Self-Determination and 
Education Assistance Act (25 U.S.C. 5381)) or through an 
urban Indian organization (as defined in section 4 of the 
Indian Health Care Improvement Act), while avoiding du-
plicative distributions to such programs or facilities.’’. 
SEC. 643. HEALTH CARE ACCESS FOR URBAN NATIVE VET-
ERANS. 
Section 405 of the Indian Health Care Improvement 
Act (25 U.S.C. 1645) is amended— 
(1) in subsection (a)(1), by inserting ‘‘urban In-
dian organizations,’’ before ‘‘and tribal organiza-
tions’’; and 
(2) in subsection (c)— 
(A) by inserting ‘‘urban Indian organiza-
tion,’’ before ‘‘or tribal organization’’; and 
(B) by inserting ‘‘an urban Indian organi-
zation,’’ before ‘‘or a tribal organization’’. 
SEC. 644. TRIBAL SCHOOL FEDERAL INSURANCE PARITY. 
Section 409 of the Indian Health Care Improvement 
Act (25 U.S.C. 1647b) is amended by inserting ‘‘or the 
Tribally Controlled Schools Act of 1988 (25 U.S.C. 2501 
et seq.)’’ after ‘‘(25 U.S.C. 450 et seq.)’’.
1327 
SEC. 645. PRC FOR NATIVE VETERANS. 
Section 405(c) of the Indian Health Care Improvement 
Act (25 U.S.C. 1645) is amended by inserting before the 
period at the end the following: ‘‘, regardless of whether such 
services are provided directly by the Service, an Indian 
tribe, or tribal organization, through contract health serv-
ices, or through a contract for travel described in section 
213(b)’’. 
Subtitle D—Public Health 
Assistance to Essential Workers 
SEC. 651. CONTAINMENT AND MITIGATION FOR ESSENTIAL 
WORKERS PROGRAM. 
(a) PROGRAM.—The Secretary, acting through the Di-
rector of the Centers for Disease Control and Prevention 
and in consultation with the Director of the National Insti-
tute for Occupational Safety and Health, shall establish a 
COVID–19 containment and mitigation for essential work-
ers program consisting of awarding grants under subsection 
(b). 
(b) GRANTS.—For the purpose of improving essential 
worker safety, the Secretary— 
(1) shall award a grant to each State health de-
partment; and 
(2) may award grants on a competitive basis to 
State, local, Tribal, or territorial health departments.
1328 
(c) USE OF FUNDS.—A State, local, Tribal, or terri-
torial health department receiving a grant under subsection 
(b) shall use the grant funds— 
(1) to purchase or procure personal protective 
equipment and rapid testing equipment and supplies 
for distribution to employers of essential workers, in-
cluding public employers; or 
(2) to support the implementation of other work-
place safety measures for use in containment and 
mitigation of COVID–19 transmission among essen-
tial workers in their workplaces, including workplaces 
of public employers. 
(d) FORMULA GRANTS TO STATE HEALTH DEPART-
MENTS.—In making grants under subsection (b)(1), the 
Secretary shall award funds to each State health depart-
ment in accordance with a formula based on overall popu-
lation size, essential workers population size, and burden 
of COVID–19. 
(e) COMPETITIVE GRANTS TO STATE, LOCAL, TRIBAL, 
AND TERRITORIAL HEALTH DEPARTMENTS.—In making 
grants under subsection (b)(2), the Secretary shall give pri-
ority to applicants demonstrating a commitment to con-
taining and mitigating COVID–19 among racial and eth-
nic minority groups who are disproportionately represented 
in essential worker settings.
1329 
(f) NO DUPLICATIVE ASSISTANCE LIMITATION.—The 
Secretary may not provide, and a State, local, Tribal, or 
territorial health department, or employer of essential work-
ers may not accept, assistance under this section for con-
tainment and mitigation of COVID–19 transmission 
among essential workers in their workplaces with respect 
to which— 
(1) the State, local, Tribal, or territorial health 
department, or employer of essential workers receives 
assistance from other sources for such purposes; or 
(2) other sources are obligated to provide assist-
ance to such health department or employer for such 
purposes. 
(g) TECHNICAL ASSISTANCE.—In carrying out the 
program under this section, the Secretary shall provide 
technical assistance to State, local, Tribal, or territorial 
health departments. 
(h) REPORT.—No later than 90 days after the date of 
enactment of this Act, and every 90 days thereafter, the Sec-
retary shall submit to the Committee on Energy and Com-
merce and the Committee on Education and Labor of the 
House of Representatives and the Committee on Health, 
Education, Labor, and Pensions of the Senate a report on 
the activities funded through this section, including—
1330 
(1) the amount expended and the awardees under 
subsection (b)(1); 
(2) the amount expended and the awardees under 
subsection (b)(2); 
(3) the total amount remaining of the amounts 
appropriated or otherwise made available to carry 
out this section under subsection (i); and 
(4) evaluating the progress of State, local, Trib-
al, and territorial health departments in reducing 
COVID–19 burden among essential workers. 
(i) CONSULTATION WITH ESSENTIAL EMPLOYERS, ES-
SENTIAL WORKERS, AND EMPLOYEE REPRESENTATIVES OF 
ESSENTIAL WORKERS.— 
(1) IN
GENERAL.—In developing the strategy 
and program under subsection (a) and in deter-
mining criteria for distribution of competitive grants 
under this section, the Secretary of Health and 
Human Services, acting through the Director of the 
Centers for Disease Control and Prevention and in 
consultation with the Director of the National Insti-
tute for Occupational Safety and Health, shall consult 
in advance with— 
(A) employers of essential workers; 
(B) representatives of essential workers; and
1331 
(C) labor organizations representing essen-
tial workers. 
(2) 
OPTIONAL
ADVANCE
CONSULTATION.—A 
State health department may, before receiving fund-
ing through a grant under this section, consult with 
employers of essential workers, representatives of 
workers, and labor organizations representing essen-
tial workers in determining— 
(A) priorities for the use of such funds; and 
(B) the distribution of COVID–19 contain-
ment and mitigation equipment and supplies. 
(j) DEFINITIONS.—In this section: 
(1) The term ‘‘essential worker’’ refers to— 
(A) the ‘‘essential critical infrastructure 
workers’’ identified in the Department of Home-
land Security’s ‘‘Advisory Memorandum on En-
suring Essential Critical Infrastructure Workers 
Ability to Work During the COVID–19 Re-
sponse’’ released on August 18, 2020 (or any suc-
cessor document); and 
(B) workers included as essential workers in 
executive orders issued by the Governor of a 
State. 
(2) The term ‘‘containment and mitigation’’ in-
cludes the use of—
1332 
(A) personal protective equipment; 
(B) other protections, including expanding 
or improving workplace infrastructure through 
engineering and work practice controls, such as 
ventilation systems, plexiglass partitions, air fil-
ters, and the use of hand sanitizer or sanitation 
supplies; 
(C) access to medical evaluations, testing 
(including rapid testing), and contact tracing; 
and 
(D) other related activities or equipment 
recommended or required by the Director of Cen-
ters of Disease Control and Prevention or re-
quired pursuant to the Occupational Safety and 
Health Act of 1970 (29 U.S.C. 651 et seq.) or a 
State plan approved pursuant to section 18 of 
that Act (29 U.S.C. 667); and 
(k) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$2,000,000,000, to remain available until expended. 
TITLE VII—VACCINE DEVELOP-
MENT, DISTRIBUTION, ADMIN-
ISTRATION, AND AWARENESS 
SEC. 701. DEFINITIONS. 
In this title:
1333 
(1) The term ‘‘ancillary medical supplies’’ in-
cludes— 
(A) vials; 
(B) bandages; 
(C) alcohol swabs; 
(D) syringes; 
(E) needles; 
(F) gloves, masks, and other personal pro-
tective equipment; 
(G) cold storage equipment; and 
(H) other products the Secretary determines 
necessary for the administration of vaccines. 
(2) The term ‘‘Secretary’’ means the Secretary of 
Health and Human Services. 
SEC. 702. VACCINE AND THERAPEUTIC DEVELOPMENT AND 
PROCUREMENT. 
(a) ENHANCING DEVELOPMENT, PROCUREMENT AND 
MANUFACTURING CAPACITY.— 
(1) IN GENERAL.—The Secretary shall, as appro-
priate, award contracts, grants, and cooperative 
agreements, and, where otherwise allowed by law, 
enter into other transactions, for purposes of— 
(A) expanding and enhancing COVID–19 
and SARS–CoV–2 vaccine and therapeutic devel-
opment and research;
1334 
(B) procurement of COVID–19 and SARS– 
CoV–2 vaccines, therapeutics, and ancillary 
medical supplies; and 
(C) expanding and enhancing capacity for 
manufacturing vaccines, therapeutics, and ancil-
lary medical supplies to prevent the spread of 
COVID–19 and SARS–CoV–2 and . 
(2) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this subsection, there is authorized to be ap-
propriated $20,000,000,000 for the period of fiscal 
years 2021 through 2025, to remain available until 
expended. 
(b) REPORT ON VACCINE MANUFACTURING AND AD-
MINISTRATION CAPACITY.—Not later than December 1, 
2020, the Secretary shall submit to the Committee on En-
ergy and Commerce and the Committee on Appropriations 
of the House of Representatives and the Committee on 
Health, Education, Labor and Pensions and the Committee 
on Appropriations of the Senate a report detailing— 
(1) an assessment of the estimated supply of vac-
cines and ancillary medical supplies related to vac-
cine administration necessary to control and stop the 
spread of SARS–CoV–2 and COVID–19, domestically 
and internationally;
1335 
(2) an assessment of current and future domestic 
capacity for manufacturing vaccines or vaccine can-
didates to control or stop the spread of SARS–CoV– 
2 and COVID–19 and ancillary medical supplies re-
lated to the administration of such vaccines, includ-
ing— 
(A) identification of any gaps in capacity 
for manufacturing; and 
(B) the effects of shifting manufacturing re-
sources to address COVID–19; 
(3) activities conducted to expand and enhance 
capacity for manufacturing vaccines, vaccine can-
didates, and ancillary medical supplies to levels suffi-
cient to control and stop the spread of SARS–CoV– 
2 and COVID–19, domestically and internationally, 
including a list and explanation of all contracts, 
grants, and cooperative agreements awarded, and 
other transactions entered into, for purposes of such 
expansion and enhancement and how such activities 
will help to meet future domestic manufacturing ca-
pacity needs; 
(4) a plan for the ongoing support of enhanced 
capacity for manufacturing vaccines, vaccine can-
didates, and ancillary medical supplies sufficient to
1336 
control and stop the spread of SARS–CoV–2 and 
COVID–19, domestically and internationally; and 
(5) a plan to support the distribution and ad-
ministration of vaccines approved or authorized by 
the Food and Drug Administration to control and 
stop the spread of SARS–CoV–2 and COVID–19, do-
mestically and internationally, including Federal 
workforce enhancements necessary to administer such 
vaccines. 
SEC. 703. VACCINE DISTRIBUTION AND ADMINISTRATION. 
(a) IN GENERAL.—The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention, 
shall— 
(1) conduct activities to enhance, expand, and 
improve nationwide COVID–19 and SARS–CoV–2 
vaccine distribution and administration, including 
activities related to distribution of ancillary medical 
supplies; and 
(2) award grants or cooperative agreements to 
State, local, Tribal, and territorial public health de-
partments for enhancement of COVID–19 and SARS– 
CoV–2 vaccine distribution and administration capa-
bilities, including— 
(A) distribution of vaccines approved or au-
thorized by the Food and Drug Administration;
1337 
(B) distribution of ancillary medical sup-
plies; 
(C) workforce enhancements; 
(D) information technology and data en-
hancements, including— 
(i) enhancements for purposes of main-
taining and tracking real-time information 
related to vaccine distribution and adminis-
tration; and 
(ii) enhancements to improve immuni-
zation information systems, including pa-
tient matching capabilities and the inter-
operability of such systems, that are admin-
istered by State, local, Tribal, and terri-
torial public health departments and used 
by health care providers and health care fa-
cilities; and 
(E) facilities enhancements. 
(b) REPORT TO CONGRESS.—Not later than December 
31, 2020, and annually thereafter, the Secretary shall sub-
mit a report to the Committee on Energy and Commerce 
and the Committee on Appropriations of the House of Rep-
resentatives and the Committee on Health, Education, 
Labor, and Pensions and the Committee on Appropriations
1338 
of the Senate detailing activities carried out and grants and 
cooperative agreements awarded under this section. 
(c) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$7,000,000,000 for the period of fiscal years 2021 through 
2025, to remain available until expended. 
SEC. 704. STOPPING THE SPREAD OF COVID–19 AND OTHER 
INFECTIOUS DISEASES THROUGH EVIDENCE- 
BASED VACCINE AWARENESS. 
(a) IN GENERAL.—The Public Health Service Act is 
amended by striking section 313 of such Act (42 U.S.C. 245) 
and inserting the following: 
‘‘SEC. 313. PUBLIC AWARENESS CAMPAIGN ON THE IMPOR-
TANCE OF VACCINATIONS. 
‘‘(a) IN GENERAL.—The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention 
and in coordination with other offices and agencies, as ap-
propriate, shall award competitive grants or contracts to 
one or more public or private entities to carry out a na-
tional, evidence-based campaign for increasing rates of vac-
cination across all ages, as applicable, particularly in com-
munities with low rates of vaccination, to reduce and elimi-
nate vaccine-preventable diseases by— 
‘‘(1) increasing awareness and knowledge of the 
safety and effectiveness of vaccines approved or au-
1339 
thorized by the Food and Drug Administration for the 
prevention and control of diseases, including COVID– 
19; 
‘‘(2) combating misinformation about vaccines; 
and 
‘‘(3) disseminating scientific and evidence-based 
vaccine-related information. 
‘‘(b) CONSULTATION.—In carrying out the campaign 
under this section, the Secretary shall consult with appro-
priate public health and medical experts, including the Na-
tional Academy of Medicine and medical and public health 
associations and nonprofit organizations, in the develop-
ment, implementation, and evaluation of the campaign 
under this section. 
‘‘(c) REQUIREMENTS.—The campaign under this sec-
tion shall— 
‘‘(1) be a nationwide, evidence-based media and 
public engagement initiative; 
‘‘(2) include the development of resources for 
communities with low rates of vaccination, including 
culturally and linguistically appropriate resources, as 
applicable; 
‘‘(3) include the dissemination of vaccine infor-
mation and communication resources to public health 
departments, health care providers, and health care
1340 
facilities, including such providers and facilities that 
provide prenatal and pediatric care; 
‘‘(4) be complementary to, and coordinated with, 
any other Federal, State, local, or Tribal efforts; 
‘‘(5) assess the effectiveness of communication 
strategies to increase rates of vaccination; and 
‘‘(6) not be used for partisan political purposes, 
or to express advocacy in support of or to defeat any 
clearly identified candidate, clearly identified ballot 
initiative, or clearly identified legislative or regu-
latory proposal. 
‘‘(d) ADDITIONAL ACTIVITIES.—The campaign under 
this section may— 
‘‘(1) include the use of television, radio, the 
internet, and other media and telecommunications 
technologies; 
‘‘(2) include the use of in-person activities; 
‘‘(3) be focused and directed to address specific 
needs of communities and populations with low rates 
of vaccination; and 
‘‘(4) include the dissemination of scientific and 
evidence-based vaccine-related information, such as— 
‘‘(A) advancements in evidence-based re-
search related to diseases that may be prevented 
by vaccines and vaccine development;
1341 
‘‘(B) information on vaccinations for indi-
viduals and communities, including individuals 
for whom vaccines are not recommended by the 
Advisory Committee for Immunization Practices, 
and the effects of low vaccination rates within a 
community on such individuals; 
‘‘(C) information on diseases that may be 
prevented by vaccines; and 
‘‘(D) information on vaccine safety and the 
systems in place to monitor vaccine safety. 
‘‘(e) EVALUATION.—The Secretary shall— 
‘‘(1) establish benchmarks and metrics to quan-
titatively measure and evaluate the campaign under 
this section; 
‘‘(2) conduct qualitative assessments regarding 
the campaign under this section; and 
‘‘(3) prepare and submit to the Committee on 
Energy and Commerce of the House of Representa-
tives and the Committee on Health, Education, 
Labor, and Pensions of the Senate an evaluation of 
the campaign under this section. 
‘‘(f) SUPPLEMENT
NOT
SUPPLANT.—Funds made 
available to carry out this section shall be used to supple-
ment and not supplant other Federal, State, local, and
1342 
Tribal public funds provided for activities described in this 
section. 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to carry out this section 
$200,000,000 for the period of fiscal years 2021 through 
2025.’’. 
(b) GRANTS TO ADDRESS VACCINE-PREVENTABLE DIS-
EASES.—Section 317 of the Public Health Service Act (42 
U.S.C. 247b) is amended— 
(1) in subsection (k)— 
(A) in paragraph (1)— 
(i) in subparagraph (C), by striking ‘‘; 
and’’ at the end and inserting a semicolon; 
(ii) in subparagraph (D), by striking 
the period at the end and inserting a semi-
colon; and 
(iii) by adding at the end the fol-
lowing: 
‘‘(E) planning, implementation, and evaluation 
of activities to address vaccine-preventable diseases, 
including activities— 
‘‘(i) to identify communities at high risk of 
outbreaks related to vaccine-preventable diseases, 
including through improved data collection and 
analysis;
1343 
‘‘(ii) to pilot innovative approaches to im-
prove vaccination rates in communities and 
among populations with low rates of vaccina-
tion; 
‘‘(iii) to reduce barriers to accessing vac-
cines and evidence-based information about the 
health effects of vaccines; 
‘‘(iv) to partner with community organiza-
tions and health care providers to develop and 
deliver evidence-based, culturally and linguis-
tically appropriate interventions to increase vac-
cination rates; 
‘‘(v) to improve delivery of evidence-based 
vaccine-related information to parents and oth-
ers; and 
‘‘(vi) to improve the ability of State, local, 
Tribal, and territorial public health departments 
to engage communities at high risk for outbreaks 
related to vaccine-preventable diseases, including, 
as appropriate, with local educational agencies 
(as defined in section 8101 of the Elementary 
and Secondary Education Act of 1965); and 
‘‘(F) research related to strategies for improving 
awareness of scientific and evidence-based vaccine-re-
lated information, including for communities with
1344 
low rates of vaccination, in order to understand bar-
riers to vaccination, improve vaccination rates, and 
assess the public health outcomes of such strategies.’’; 
and 
(B) by adding at the end the following: 
‘‘(5) In addition to amounts authorized to be appro-
priated by subsection (j) to carry out this subsection, there 
is authorized to be appropriated to carry out this subsection 
$750,000,000 for the period of fiscal years 2021 through 
2025.’’; and 
(2) by adding at the end the following: 
‘‘(n) VACCINATION DATA.— 
‘‘(1) 
IN
GENERAL.—The 
Secretary, 
acting 
through the Director of the Centers for Disease Con-
trol and Prevention, shall expand and enhance, and, 
as appropriate, establish and improve, programs and 
conduct activities to collect, monitor, and analyze 
vaccination coverage data to assess levels of protection 
from vaccine-preventable diseases including COVID– 
19, including by— 
‘‘(A) assessing factors contributing to un-
derutilization of vaccines and variations of such 
factors; and
1345 
‘‘(B) identifying communities at high risk 
of outbreaks associated with vaccine-preventable 
diseases. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this section $50,000,000 for the period of fiscal years 
2021 through 2025.’’. 
(c) 
SUPPLEMENTAL
GRANT
FUNDS.—Section 
330(d)(1) of the Public Health Service Act (42 U.S.C. 
254b(d)(1)) is amended— 
(1) in subparagraph (F), by striking ‘‘and’’ at 
the end; 
(2) in subparagraph (G), by striking the period 
at the end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(H) improving access to recommended im-
munizations.’’. 
(d) UPDATE OF 2015 NVAC REPORT.—The National 
Vaccine Advisory Committee established under section 2105 
of the Public Health Service Act (42 U.S.C. 300aa–5) shall, 
as appropriate, update the report entitled, ‘‘Assessing the 
State of Vaccine Confidence in the United States: Rec-
ommendations from the National Vaccine Advisory Com-
mittee’’, approved by the National Vaccine Advisory Com-
1346 
mittee on June 10, 2015, with respect to factors affecting 
childhood vaccination. 
TITLE VIII—OTHER MATTERS 
SEC. 801. NON-DISCRIMINATION. 
(a) IN GENERAL.—Notwithstanding any provision of 
a covered law (or an amendment made in any such provi-
sion), no person otherwise eligible shall be excluded from 
participation in, denied the benefits of, or subjected to dis-
crimination in the administration of, programs and serv-
ices receiving funding under a covered law (or an amend-
ment made by a provision of such a covered law), based 
on any factor that is not merit-based, such as age, dis-
ability, sex (including sexual orientation, gender identity, 
and pregnancy, childbirth, and related medical conditions), 
race, color, national origin, immigration status, or religion. 
(b) COVERED LAW DEFINED.—In this section, the term 
‘‘covered law’’ includes— 
(1) this Act (other than this section); 
(2) title I of division B of the Paycheck Protec-
tion Program and Healthcare Enhancement Act 
(Public Law 116–139); 
(3) subtitles A, D, and E of title III of the 
CARES Act (Public Law 116–136); 
(4) division F of the Families First Coronavirus 
Relief Act (Public Law 116–127); and